Andrea Pederzolli

Pedius is a communication system that allows deaf people to make normal phone calls. Use it in your everyday life to make important calls such as booking doctors appointments or making reservations, or to call family, friends and coworkers. Once you download the smartphone app you can start a conversation by either typing or speaking a message. The recipient will listen on their end and reply, and you will immediately read a transcription of what he or she just said. Pedius gives you the freedom to have real-time conversations when you need to call a plumber, book a table at your favourite restaurant, or talk to your doctor. Pedius also offers companies the chance of enabling accessible phone services to their deaf customers.

Laboratori Italiani Riuniti è una società specializzata nei servizi di analisi cliniche di laboratorio e di specialistica ambulatoriale.

We are a clinical stage biopharmaceutical company developing developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases. We have developed two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and auto-immune diseases: - OncoMimics™: highly effective, off-the-shelf therapeutic vaccines against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin B-cell lymphomas. - EndoMimics™: a pipeline of next generation bioactives acting like human hormones or cytokines for the treatment of immune diseases. EB1010, the lead candidate, is a potent local inducer of IL-10 designed to provide improved therapeutic outcomes for patients with IBD. In addition, Enterome’s clinical candidate sibofimloc (also referred to as TAK-018) is advancing through a Phase 2 clinical trial in post-operative Crohn’s disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.

Pedius is a communication system that allows deaf people to make normal phone calls. Use it in your everyday life to make important calls such as booking doctors appointments or making reservations, or to call family, friends and coworkers. Once you download the smartphone app you can start a conversation by either typing or speaking a message. The recipient will listen on their end and reply, and you will immediately read a transcription of what he or she just said. Pedius gives you the freedom to have real-time conversations when you need to call a plumber, book a table at your favourite restaurant, or talk to your doctor. Pedius also offers companies the chance of enabling accessible phone services to their deaf customers.

Laboratori Italiani Riuniti è una società specializzata nei servizi di analisi cliniche di laboratorio e di specialistica ambulatoriale.

We are a clinical stage biopharmaceutical company developing developing breakthrough immunomodulatory drugs for the treatment of cancer and inflammatory diseases. We have developed two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer and auto-immune diseases: - OncoMimics™: highly effective, off-the-shelf therapeutic vaccines against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463 is in a Phase 1/2 clinical trial for indolent non-Hodgkin B-cell lymphomas. - EndoMimics™: a pipeline of next generation bioactives acting like human hormones or cytokines for the treatment of immune diseases. EB1010, the lead candidate, is a potent local inducer of IL-10 designed to provide improved therapeutic outcomes for patients with IBD. In addition, Enterome’s clinical candidate sibofimloc (also referred to as TAK-018) is advancing through a Phase 2 clinical trial in post-operative Crohn’s disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.

Xyence Capital SGR is an independent fund manager focused on the Italian Life Sciences industry, currently managing two Funds.